Chordate Medical receives registration of the trademark Ozilia®

Chordate Medical has obtained the registration of the trademark Ozilia® in the EU from EUIPO (EU Intellectual Property Office) in trademark classes 9 and 10. The company is now proceeding with applications in other suitable countries based on the priority period allowed by the registration.

The new trademark represents a strategic step in the roll-out and commercialization of the migraine treatment in Chordate Medical’s focus markets. Ozilia® replaces K.O.S as product name in all markets where the company operates.

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact